T2 Biosystems, Inc. (0A57.L)
| Previous close | 4.9100 |
| Open | 5.1000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 4.9200 - 5.1000 |
| 52-week range | 3.5166 - 74.0800 |
| Volume | |
| Avg. volume | 1,849 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireT2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024
LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2024 and business updates after market close on Monday, July 29, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by acce
- GlobeNewswire
T2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau Distributor
LEXINGTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Hong Kong and Macau. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor. The execution of this exc
- GlobeNewswire
T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements
LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued list
